Patent Description:
Inflammatory response plays an important role in the pathology of most diseases, including liver damage, which lead to a progressive deterioration of metabolic functions. In clinical practice, there is a large number of non-steroidal anti-inflammatory drugs (NSAIDs) for alleviating pain and inflammation. However, NSAIDs have adverse side effects whose risk of onset is higher the higher the dose and/or the longer the duration over time. Irritation of the digestive tract, hepatotoxicity, high blood pressure, fluid retention, kidney problems, heart problems, and/or rashes are included among the unwanted side effects which may occur. There is therefore an unmet medical need to find other compounds that may perform an anti-inflammatory and cytoprotective function without exhibiting the side effects described in the preceding paragraph, particularly in the treatment of NRF2-related diseases that present with chronic inflammation and oxidative stress, comprising liver disease, preferably fatty liver disease.

Precisely for the purpose of solving this technical problem, compounds with these properties have been developed in the present invention based on the activation of NRF2 (nuclear factor (erythroid-derived <NUM>)-like <NUM>) transcription factor by means of a completely novel technique consisting of interrupting its interaction with the E3 ligase adaptor protein referred to as β-TrCP (beta-transducin repeat-containing E3 ubiquitin protein ligase). Contrary to other strategies that activate NRF2, the targeted disruption of the NRF2/βTrCP interaction results in a moderate induction of its homeostatic functions in the range of physiological activity.

<CIT> discloses <NUM>',<NUM>',3a'-6a'-tetrahydro-<NUM>'H-spiro[indoline-<NUM>,<NUM>'-pyrrolo[<NUM>,<NUM>-c]pyrrole]-<NUM>,<NUM>',<NUM>',(<NUM>'H)-trione (SIPP) compounds for use in the treatment of i. cholestatic liver disease which differ from those presently claimed in that they lack the CH2-<NUM>-indolyl moiety. <CIT> discloses SIPP compounds for use in the treatment i. In vitro method for identifying compounds for the treatment of NRF2-related diseases caused by inflammatory liver injury, hepatitis and liver diseases in general by identifying the modulation of GSK-3β/NRF2/β-TrCP signaling axis (inter alia in the Neh6 domain) are disclosed in the art (see <NPL>) and <NPL>).

As indicated above, the present invention relates to NRF2-βTrCP interaction inhibitors for use in the treatment of NRF2-related diseases (see <FIG>) which show chronic inflammation and oxidative stress, comprising liver disease, preferably fatty liver disease. The protein βTrCP binds to NRF2 and sends it to degradation by the ubiquitin/proteasome pathway. The compounds of the present invention prevent this interaction and, therefore, the degradation of NRF2 through this pathway is prevented, giving rise to maintenance of their functional levels and their homeostatic activity. Importantly, this invention is not connected with the widely studied alternative for the degradation of NRF2, based on its binding with KEAP1. This invention is different in two respects: a) this invention refers to the disruption of NRF2/βTrCP which is a different mechanism to the KEAP1/NRF2, and b) the molecules object of this invention induce a gentler activation of NRF2 in comparison with the already described inhibitors of KEAP1/NRF2. This is of special interest because KEAP1/NRF2 inhibitors lead to a supraphysiological excess of NRF2 activation that can trigger possible unwanted effects.

Therefore, the first aspect of the present invention relates to NRF2-βTrCP interaction inhibitors, wherein the inhibitor can be optionally characterized by Formula (I), or its derivative salts,
<CHM>
wherein:.

for use in the treatment of fatty liver disease. This invention is thus particularly focused on the treatment of liver diseases associated with low-grade chronic inflammation and its impact on the development of fatty liver and progression to fibrosis and cirrhosis.

In a preferred aspect of the invention, the NRF2-βTrCP interaction inhibitor is characterized by Formula (II) (hereinafter also referred to as PHAR),
<CHM>
or its derivative salts.

The second aspect of the present invention relates to a pharmaceutical composition comprising the NRF2-βTrCP interaction inhibitor of Formula I or II, or derivative salts thereof, and optionally pharmaceutically acceptable vehicles or excipients, for use in the treatment of fatty liver disease. Alternatively, the present invention relates to a method for the treatment of fatty liver disease comprising the administration of a therapeutically effective dose or amount of a pharmaceutical composition comprising the NRF2-βTrCP interaction inhibitor of Formula I or II, or derivative salts thereof.

The third aspect of the present invention relates to an in vitro method for identifying and producing compounds for the treatment of fatty liver disease, which comprises: a) determining if the inhibition of NRF2-βTrCP interaction by the candidate compound has taken place, and b) wherein if the inhibition of NRF2-PTrCP interaction has taken place, it is indicative of the selected compound being effective in the treatment of fatty liver disease.

Different approaches have been used to determine if the compound inhibits NRF2-βTrCP interaction:.

The following terms are defined for a better interpretation of the present invention:.

The present invention is illustrated by means of the following examples without the intention of limiting the scope of protection of the invention.

In order to find molecules capable of specifically interrupting β-TrCP-NRF2 interaction, a virtual analysis was carried out by means of molecular modeling and molecular dynamics tools based on the structural similarity of <NUM>,<NUM> natural compounds obtained from the "ZINC natural products" and the "National Center for Biotechnology Information (NCBI) PubChem database" compound libraries (<FIG>).

For this in silico study, the crystallographic structure PDB: 1P22 of β-TrCP which is published in the Protein Data Bank database and complexed with Skp1-β-Catenin was used. The specific 3D preparation and editing of β-TrCP was performed using the tool Pymol software v <NUM>. <NUM>, thereby obtaining the Skp1- and β-catenin-free β-TrCP molecule. The present group has previously characterized the most relevant moieties at the site of interaction between β-TrCP WD40 domain and the phosphodegron generated by GSK-3β in the Neh6 domain of NRF2. This NRF2 interaction site was used to identify the compounds having the highest theoretical affinity for β-TrCP. In this study, the AutoDock Vina tool which incorporates evolutionary and Lamarckian genetic algorithm methods, among others, has been used, allowing ligand flexibility to be modeled, while the receptor is kept rigid. Moreover, in addition to its theoretical efficacy for inhibiting β-TrCP-NRF2 interaction, ADMET properties (absorption, biodistribution, the speed at which it is metabolizes, excretion, and toxicity) were analyzed using DataWarrior software and the ADMETsar online tool.

Based on the data obtained from molecular modeling, <NUM> compounds were selected based on their Gibbs free energy (ΔG), meeting the criterion of ≤ -<NUM> kcal/mol. Then, those compounds with ADMET properties outside the established optimal ranges were eliminated. Lastly, due to the high structural homology among the <NUM> selected candidates, they were grouped into <NUM> clusters having at least <NUM>% homology.

Since molecular modeling by AutoDock Vina only provides a static idea of interaction, to fine tune the selection of the best theoretical candidates, theoretical models of molecular dynamics are carried out using YASARA software. The purpose is to check whether the interactions established by the compounds selected in the first part of the process with β-TrCP are stable during the specific study time (<NUM> ns). Based on these results, <NUM> candidates (representing <NUM> clusters having a different homology) with the theoretical capacity to establish stable interactions with β-TrCP throughout the study time were obtained.

By analyzing the computational parameters obtained for PHAR (<FIG>), the molecular modeling results showed that the compound binds to β-TrCP with a theoretical value of ΔG = -<NUM> kcal/mol. Using the PHAR pose with the lowest free energy derived from molecular modeling, the interactions established by the compound with β-TrCP moieties were studied in detail, establishing as selection criterion a distance less than or equal to <NUM>Å (<FIG>). The purpose was to enable evaluating the capacity of the compound to interrupt β-TrCP-phospho-NRF2 (pNRF2) interactions. The β-TrCP moieties of interest involved in the hydrophobic interactions with pNRF2 are: Arg521, Phe523, Tyr271, Arg474, Ala <NUM>, Asn394, and Leu351. Meanwhile, the electrostatic interactions involve the following β-TrCP moieties: Arg285, Ser325, Lys365, Tyr438, Arg431, Asn394, and Gly408. As shown in <FIG>, PHAR establishes interaction with most of the moieties involved in the hydrophobic pNRF2-β-TrCP interaction, with the exception of Tyr271. In contrast, only interaction with Ser448, involved in electrostatic interactions, could be inhibited by PHAR. It must be pointed out that PHAR is capable of establishing interaction with more β-TrCP moieties other than those listed above (magenta, <FIG>). This could entail the advantage of taking up more space at the site where it interacts with pNRF2, complicating the binding capacity thereof.

In turn, as shown in <FIG>, the analysis of molecular dynamics showed that the interaction with β-TrCP, established by PHAR, is stable for at least <NUM> ns. In contrast, <FIG> shows how the interaction it establishes with KEAP1 is unstable since the compound leaves the binding site during this time. Again, long-term analysis of interacting moieties corroborated, by means of molecular dynamics, that PHAR interacts with many of the moieties involved in pNRF2/β-TrCP interaction such as: Asn394, Gly408, Arg431, Gly432, Ser448, Leu472, Arg474, Phe523 (<FIG>). With respect to ADMET predictions (<FIG>), PHAR is within the optimal ranges corresponding to Lipinski's rule.

Therefore, computational analysis shows that PHAR could indeed interact with β-TrCP, but not with KEAP1, in the key moieties of the NRF2 binding site, and could thereby compete with the binding of NRF2 to β-TrCP.

In order to empirically determine if PHAR activates NRF2, mouse embryo fibroblasts (MEFs) were treated with several doses of the compound (<NUM>, <NUM>, and <NUM>) for <NUM> and with <NUM> of sulforaphane (SFN), one of main electrophilic activators of NRF2, used as a positive control. PHAR induced NRF2 accumulation, although to a slightly lesser extent than the accumulation induced by SFN. This NRF2 accumulation was reflected in an increase, mainly with the dose of <NUM>, in the levels of one of its best characterized targets: heme oxygenase-<NUM> (HO-<NUM>) (<FIG>).

Moreover, a time course of NRF2 activation with PHAR (<NUM> for <NUM>, <NUM>, and <NUM>) or with SFN (<NUM>, <NUM>) was done as a positive control. PHAR induced NRF2 accumulation <NUM> after treatment which was similar to the induction generated by SFN. Said accumulation correlated with the increase in HO-<NUM> levels after <NUM> (<FIG>).

Finally, the transcriptional activity of NRF2 was corroborated by means of luciferase assays using the reporter cell line MCF-<NUM> c32 ARE-LUC. It is observed that PHAR (<NUM>, <NUM>) produces a ~<NUM>-fold increase in luciferase activity, similar to that obtained with the positive control (SFN, <NUM>, <NUM>) (<FIG>). Cell viability associated with treatment, evaluated by means of an MTT assay, demonstrated that the compound does not present toxicity at any of the doses used (<FIG>). Finally, said transcriptional activity was corroborated in MEFs by means of evaluating the expression levels of several NRF2-regulated genes after treatment with PHAR (<NUM>, <NUM>). The analyzed targets were Hmox1, Nqo1, Aox1, Gclc, and Gclmy an increase in the corresponding transcripts was observed in all the cases (<FIG>).

As a whole, these results indicate that PHAR stabilizes NRF2 levels, and as a result increases the expression of its target genes.

From a viewpoint of biopharmaceutical usefulness, it is important to determine if PHAR acts on KEAP1/NRF2 interaction, or if it represents, in contrast, a novel approach directed specifically at β-TrCP/NRF2 interaction. For this purpose, MEFs originating from KEAP1 knock-out (Keap1-/-) and wild type (Keap1+/+) mice from the same litter (<FIG>) were used. NRF2 and HO-<NUM> induction was similar in both cell lines treated with PHAR (<NUM>, <NUM>, <NUM>, and <NUM>) (<FIG>). The same result was obtained upon analyzing the mRNA levels of other NRF2 targets (<FIG>). As an additional control, the HO-<NUM> levels in MEFs originating from NRF2 knock-out (Nrf2-/-) and wild-type (Nrf2+/+) mice from the same litter were analyzed by immunoblot. Both cell types were incubated with PHAR (<NUM>, <NUM>, <NUM>, and <NUM>). MEFs originating from Nrf2+/+ mice showed a significant increase in HO-<NUM> which was not observed in MEFs originating from Nrf2-/- mice (<FIG>), indicating that NRF2 is essential for the induction of HO-<NUM> by PHAR. The same result was obtained upon analyzing the mRNA levels of several NRF2 targets in both cell types (<FIG>). Therefore, PHAR induces NRF2 independently of KEAP1 and said activation is responsible for the increase in the expression of its target genes.

In silico studies suggested that PHAR increases NRF2 levels by means of inhibiting NRF2-β-TrCP interaction. To confirm this, first, we performed an in vitro ubiquitination assay to see if PHAR prevents the ubiquitination of NRF2 by βTrCP. For βTrCP to be able to recognize and degrade NRF2, NRF2 must be labelled first by phosphorylation at serines <NUM>, <NUM>, <NUM> and <NUM>, located in the Neh6 domain, that are carried out, at least in part, by GSK-3β. In order to get the phosphorylated NRF2, we performed an in vitro GSK-3β kinase assay with recombinant NRF2-DETGE, for <NUM> at <NUM>. Western blot analysis revealed that the described serines were adequately phosphorylated (<FIG>). Next, both the phosphorylated and non-phosphorylated substrates were subjected to in vitro ubiquitination asssay in the presence and absence of PHAR. As shown in <FIG>, the substrate was polyubiquitinated to a greater extent when it was previously phosphorylated. Interestingly, this polyubiquitination was considerably lower when the PH was present. Next, we performed a dose curve with the same procedure (<FIG>) and PHAR starts to reduce substrate polyubiquitination from the <NUM> concentration.

The next approach was to inhibit the PI3K/AKT signaling pathway, leading to GSK-3β activation, with the PI3K inhibitor, LY294002. As a result, NRF2 is phosphorylated in its Neh6 domain and marked for degradation by means of interaction with β-TrCP. Therefore, if PHAR inhibits β-TrCP-NRF2 interaction, according to in silico predictions, NRF2 levels will remain stable independently of the activation and phosphorylation by GSK-3β. Furthermore, to once again rule out a possible KEAP1-mediated alternative mechanism, MEFs originating from Keap1-/- mice were used. These cells were pretreated with <NUM> of PHAR or DMSO as a vehicle for <NUM> and treatment with LY294002 (<NUM>, <NUM>, <NUM>, <NUM>, <NUM>, and <NUM>) was then carried out LY294002 caused a reduction of pSer473-AKT (by inactivating it) and pS9-GSK3 (by activating it) (<FIG>), and furthermore caused a drop in NRF2 levels which can be observed mainly after <NUM> and <NUM> of treatment. In contrast, pre-treatment with PHAR not only prevented LY294002-induced NRF2 degradation, but furthermore favored NRF2 accumulation independently of the activation of GSK3-β/β-TrCP (<FIG>). Therefore, these results suggest that PHAR promotes NRF2 accumulation by means of inhibiting interaction with β-TrCP.

In other experiments, silencing of the two isoforms described for β-TrCP (β-TrCP1 and β-TrCP2) was performed in MEFs originating from Keap1-/- mice. Silencing was performed by means of infection with lentiviral vectors shRNA control (shCTRL) or β-TrCP1 and β-TrCP2 (sh β-TrCP1/<NUM>) for <NUM> days followed by selection of the infected cells with puromycin. Once silencing was performed, the cells were treated with PHAR (<NUM>, <NUM>, <NUM>, and <NUM>). Although the silencing achieved was about <NUM>% for both isoforms (<FIG>), this was sufficient to observe a significant increase in levels of β-catenin protein, used as the β-TrCP silencing control as it is one of its main targets (<FIG>). In these conditions, it can be seen in shCTRL cells that PHAR causes an increase in NRF2 levels from <NUM> to <NUM> after sustained treatment. In contrast, the partial silencing of β-TrCP <NUM>/<NUM> caused a slight increase in baseline NRF2 levels compared with shCTRL. However, although NRF2 accumulation occurred as a result of the treatment (probably due to the silencing achieved not being <NUM>%), this accumulation was significantly lower compared with shCTRL cells (<FIG>). Likewise, HO-<NUM> accumulation was lower in cells lacking β-TrCP1/<NUM> (<FIG>). The mRNA levels corresponding to conventional NRF2 targets, Hmox1 and Nqo1, confirmed the result obtained in protein, seeing that the induction generated by PHAR is lost with the silencing of both isoforms of β-TrCP (<FIG>). Therefore, it can be concluded that the mechanism of action of the PHAR compound is mediated by its capacity to inhibit β-TrCP-NRF2 interaction.

Once the mechanism of action of PHAR was deciphered, the capacity thereof to carry out protection against general lipopolysaccharide (LPS)-induced inflammation was evaluated. The NRF2/HO-<NUM> axis contributes to inflammation resolution through direct and indirect mechanisms. Direct mechanisms include transcripcional induction of anti-inflammatory genes (MARCO, CD36), as well as transcriptional repression of pro-inflammatory genes (IL6, IL1β). Indirect mechanisms involve the inhibition of reactive oxygen species and reactive nitrogen species (ROS/RNS) or of the migration/infiltration of immune cells. Furthermore, the NRF2-ARE pathway is in equilibrium with the NF-κB pro-inflammatory pathway.

First, an established mouse macrophage cell line (Raw264. <NUM>) is used and subjected to pre-treatment with a vehicle (DMSO) or PHAR (<NUM>, <NUM>) to obtain increased NRF2 and HO-<NUM> levels. The cells were then stimulated with LPS (<NUM> ng/ml, <NUM>, <NUM>, or <NUM>) to trigger an inflammatory response. After <NUM> of treatment, the LPS indeed caused an increase of several inflammatory markers: p65, pre-IL1β, NOS2, and COX2 (<FIG>). In contrast, pretreatment with PHAR increased NRF2 and HO-<NUM> levels (<FIG>) but, furthermore, mitigated the increase in inflammatory parameters determined by immunoblot (<FIG>) or by mRNA levels (Il1β, Cox2, Nos2) (<FIG>). Furthermore, other pro-inflammatory cytokines (Il6 and Tnfa) also experienced a significantly milder induction in cells pretreated with PHAR (<FIG>). Therefore, PHAR reduces the inflammatory response in response to LPS in Raw264. <NUM> cells.

As a complementary approach, peritoneal macrophages extracted from Nrf2+/+ mice and knock-in mice generated in the laboratory having <NUM> serines substituted with alanines in critical positions for phosphorylation by priming kinase/priming kinases and by GSK-3β (Serines <NUM>, <NUM>, <NUM>, and <NUM>) were used. Both cell types were pretreated with DMSO or PHAR (<NUM>, <NUM>) and then stimulated with LPS (<NUM> ng/ml, <NUM>). In these cell models, LPS caused an increase in inflammatory markers in peritoneal macrophages originating from Nrf2+/+ mice (<FIG> left panel and <FIG>). Pretreatment with PHAR caused a significant increase in NRF2 and HO-<NUM> protein levels (<FIG> left panel and <FIG>) but the production of inflammatory markers was significantly lower in those analyzed at the protein level (pre-IL1β, COX2, and NOS2) (<FIG> left panel and <FIG>) and mRNA level (Il1β, Cox2, Nos2, Il6, and Tnfα) (<FIG>). In peritoneal macrophages derived from 4KI (Nrf2-4KI) mice, NRF2 induction in response to PHAR was considerably lower. In contrast, the same HO-<NUM> induction in response to treatment was obtained (<FIG> right panel, and <FIG>). Interestingly, the protective effect against the PHAR-mediated inflammatory response was lost in almost all the inflammatory markers analyzed both in protein (<FIG> right panel and <FIG>) in mRNA (<FIG>). Therefore, considering all the results as a whole, it can be concluded that PHAR is an anti-inflammatory compound whose mechanism of action is the activation of NRF2 by interrupting the interaction thereof with β-TrCP.

Once the mechanism of action of PHAR was deciphered, the capacity thereof to induce NRF2 levels in a murine model was evaluated. C57BL/<NUM> mice received a single intraperitoneal (IP) injection of <NUM>/kg PHAR (Tween-<NUM> + PBS, <NUM>:<NUM>) or <NUM>/kg of SFN (saline) as a positive control. The UV spectrum derived from the HPLC-MS study of the PHAR compound disolved in methanol alone helped the identification of the peak associated with the compound for subsequent identification in the tissue analysis. As shown in <FIG>, the PHAR UV spectrum resulted in a peak at about <NUM> minutes of elution with an associated mass of <NUM>/mol, as expected. Taking this as a reference point, liver tissue analysis was performed to check for the presence of PHAR therein. In <FIG>, the untreated mice showed two non-specific peaks at about <NUM> and <NUM> minutes of elution (referred to in <FIG> with letters A and B) identified by means of UV absorbance. However, PHAR-treated mice further showed a new peak at ~<NUM> minutes of elution (letter C). This new peak in treated mice corresponded with the presence of the compound since the mass analysis showed the existence of a mass with a value of <NUM>/mol identical to the mass obtained in <FIG>. Likewise, analysis of liver NRF2 levels showed significant NRF2 accumulation <NUM> after the administration of PHAR which was very similar to the accumulation caused by SFN (<FIG>). However, this accumulation did not result in increased HO-<NUM> levels, presumably because the duration of treatment was too short to generate an accumulation thereof.

For this reason, C57BL/<NUM> mice were treated daily by IP route for <NUM> days with <NUM>/kg of vehicle or <NUM>/kg of PHAR. A significant increase of NRF2 and HO-<NUM> in liver (<FIG>) was observed <NUM> minutes after the last administration of the compound. By contrast, the levels of NRF2 and HO1 in brain were not modified, In kidney the basal HO1 levels were higher than in liver, but they were not further increased by PHAR. These results indicate that the invention claimed with formula II is active in liver but does not discard that specific molecules included in formula I might also have a therapeutic value in other organs in case of a different pharmacodynamics.

Preliminary safety studies have been performed in <NUM>-week-old control and streptozotocin (STZ) -treated mice. These mice were subjected to an I. P treatment of <NUM>/kg of vehicle (Tween-<NUM>: PBS, <NUM>:<NUM>) or PHAR for <NUM> weeks with <NUM> weekly doses. As seen in <FIG>, the mice did not lose weight during treatment, despite the fact that weight loss is a very sensitive indicator of disease in mice. On the other hand, serum levels of albumin, total protein and two transaminases (AST and ALT) were analyzed. As shown in <FIG>, these parameters showed values within normal ranges after <NUM> weeks. Therefore, toxicity data previously obtained in cell culture (<FIG>) together with these preliminary toxicological data obtained in mice suggest that prolonged administration of PHAR is safe.

Once the in vitro anti-inflammatory effects of PHAR and its capacity to increase NRF2 and HO-<NUM> levels in a model in vivo were demonstrated, it was evaluated whether the compound was capable of inhibiting LPS-mediated signaling in a murine model. To that end, <NUM> wild-type C57BL/<NUM> mice were divided into <NUM> experimental groups: vehicle (experimental group <NUM>), PHAR (experimental group <NUM>), LPS (<NUM>), and LPS+PHAR (<NUM>). After obtaining results as promising as those described in detail in Example <NUM>, the inventors decided to carry out the same experimental protocol. Briefly, the mice were treated daily by IP route with <NUM>/kg of PHAR (experimental groups <NUM> and <NUM>) or vehicle (groups <NUM> and <NUM>). Two hours after the second-to-last administration, experimental groups <NUM> and <NUM> were treated by IP route with <NUM>/kg of LPS. Lastly, the last dose of PHAR was administered on the last day and <NUM> after the administration of LPS, all the mice were sacrificed by extracting the liver protein and total RNA. Liver tissue protein analysis showed an increase in NRF2 levels derived from treatment with PHAR with a synergistic effect when treatment was performed with PHAR+LPS (<FIG>). The clearest result was obtained when analyzing its target HO-<NUM>, where induction mediated by the compound could be clearly seen, and the same synergistic effect was again observed with combined treatment (<FIG>). The analysis of the mRNA levels of different pro-inflammatory cytokines (Il1β, <NUM>, and Tnfα) showed a significant increase as a result of treatment with LPS, as expected. In this context, prior treatment with PHAR favored a significant reduction in the production of said cytokines (<FIG>). The histochemical analysis, using H&E, revealed that the liver structure remains unaltered with the PHAR treatment, further supporting a safety profile. Furthermore, immunohistochemical staining of the inflammatory activation of hepatic macrophages (Kupffer cells) by anti-F4/<NUM> immunostaining revealed that LPS significantly activates these macrophages, as expected, and that this activation is greatly attenuated with PHAR treatment. Therefore, these obtained results confirm that treatment with PHAR favors an environment which protects against inflammation in mice in response to LPS.

As previously described, the STAM model is a murine model used for the study of non-alcoholic fatty liver disease (NAFLD), as well as for the search of new effective treatments. This model is generated by the subcutaneous injection of streptozotocin (STZ) in <NUM>-<NUM> day old neonatal C57BL/6J mice followed by a high-fat diet, administered after <NUM> weeks of age. STZ produces a pancreatic lesion that leads to the appearance of hyperglycemia that, together with the high-fat diet, gradually leads to different stages of progressive liver damage: steatosis (week <NUM> post-STZ injection); Inflammatory NASH (week <NUM>); NASH fibrosis (week <NUM>) and, finally, hepatocarcinoma (week <NUM>). The pathogenesis of NAFLD is closely related to the appearance of reactive oxygen species, chronic low-grade inflammation, and changes in lipid metabolism. For this reason, we determined whether PHAR, as an inducer of NRF2, could attenuate the inflammatory response. Specifically, we treated mice in the steatosis stage (week <NUM>), <NUM> days a week with an IP administration of <NUM>/kg in order to analyze if it prevents progression to the next stage (NASH). As shown in <FIG>, H&E staining evidenced that the liver structure was similar in PHAR-treated and untreated STAM mice. On the other hand, lipid histochemistry using oil red showed accumulation of liver fat, corroborating the proper functioning of the model. In this case, PHAR significantly decreased the amount of accumulated liver fat. Analysis of liver fat quantity, measured by MRI at the end of treatment, revealed that PHAR slows the accumulation of liver fat in the STAM model (<FIG>). We analyzed the mRNA levels of various genes involved in fatty acid metabolism and found that PHAR produces a metabolic change consistent with the increase in lipid catabolism, evident in the expression of Cpt1a (carnitine palmitoyl transferase I) that facilitates the mitochondrial degradation of fatty acids, and in the decrease in their synthesis, by decreasing of Fasn (fatty acid synthase) expression (<FIG>). Finally, PHAR showed in the liver a tendency to decrease the expression of the pro-inflammatory cytokines Tnf, il6 and Infg and to increase the anti-inflammatory cytokines Il10 and Il4 (<FIG>). Altogether, we conclude that PHAR slows down the accumulation of fat and, therefore, prevents the appearance of NASH.

Claim 1:
An NRF2-βTrCP interaction inhibitor, characterized by Formula (I) or its derivative salts,
<CHM>
wherein:
• n can be <NUM> or <NUM>,
• R<NUM> can be O<NUM>CCH<NUM> or a six-membered ring for forming a benzodioxane, benzomethylenedioxy, or naphthalene substituent;
• R<NUM> can be H or a six-membered ring for forming a benzodioxane, benzomethylenedioxy, or naphthalene substituent;
• R<NUM> can be H or CH<NUM>;
• R<NUM> can be H or CH<NUM>; and
• R<NUM> can be H, Cl, or CH<NUM>.
for use in the treatment of fatty liver disease.